Changmao Biochemical Engineering Past Earnings Performance
Past criteria checks 0/6
Changmao Biochemical Engineering's earnings have been declining at an average annual rate of -15.3%, while the Chemicals industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 5.2% per year.
Key information
-15.3%
Earnings growth rate
-15.3%
EPS growth rate
| Chemicals Industry Growth | 10.2% |
| Revenue growth rate | 5.2% |
| Return on equity | -13.3% |
| Net Margin | -13.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist
Aug 02
Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled
Nov 18We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability
Apr 28Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns
Aug 03Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital
May 04Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield
Feb 23Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?
Jan 26
A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary
Dec 02Revenue & Expenses BreakdownBeta
How Changmao Biochemical Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 637 | -86 | 83 | 0 |
| 30 Sep 23 | 640 | -21 | 86 | 0 |
| 30 Jun 23 | 644 | 45 | 88 | 0 |
| 31 Mar 23 | 687 | 63 | 93 | 0 |
| 31 Dec 22 | 730 | 81 | 97 | 0 |
| 30 Sep 22 | 707 | 90 | 95 | 0 |
| 30 Jun 22 | 684 | 99 | 93 | 0 |
| 31 Mar 22 | 616 | 79 | 88 | 0 |
| 31 Dec 21 | 548 | 58 | 82 | 0 |
| 30 Sep 21 | 509 | 30 | 80 | 0 |
| 30 Jun 21 | 471 | 2 | 79 | 0 |
| 31 Mar 21 | 457 | 9 | 78 | 0 |
| 31 Dec 20 | 444 | 17 | 77 | 0 |
| 30 Sep 20 | 430 | 24 | 68 | 0 |
| 30 Jun 20 | 417 | 31 | 58 | 0 |
| 31 Mar 20 | 456 | 45 | 66 | 0 |
| 31 Dec 19 | 495 | 58 | 75 | 0 |
| 30 Sep 19 | 557 | 69 | 78 | 0 |
| 30 Jun 19 | 620 | 79 | 81 | 0 |
| 31 Mar 19 | 629 | 65 | 80 | 0 |
| 31 Dec 18 | 639 | 51 | 79 | 0 |
| 30 Sep 18 | 633 | 34 | 82 | 0 |
| 30 Jun 18 | 626 | 17 | 84 | 0 |
| 31 Mar 18 | 629 | 10 | 83 | 0 |
| 31 Dec 17 | 631 | 3 | 81 | 0 |
| 30 Sep 17 | 625 | 8 | 81 | 0 |
| 30 Jun 17 | 619 | 13 | 82 | 0 |
| 31 Mar 17 | 607 | 23 | 81 | 0 |
| 31 Dec 16 | 594 | 33 | 80 | 0 |
| 30 Sep 16 | 569 | 42 | 78 | 0 |
| 30 Jun 16 | 544 | 51 | 76 | 0 |
| 31 Mar 16 | 530 | 48 | 76 | 0 |
| 31 Dec 15 | 515 | 45 | 75 | 0 |
| 30 Sep 15 | 519 | 40 | 73 | 0 |
| 30 Jun 15 | 523 | 35 | 72 | 0 |
| 31 Mar 15 | 543 | 36 | 73 | 0 |
| 31 Dec 14 | 562 | 37 | 73 | 0 |
| 30 Sep 14 | 606 | 48 | 78 | 0 |
| 30 Jun 14 | 650 | 58 | 82 | 0 |
| 31 Mar 14 | 677 | 66 | 84 | 0 |
| 31 Dec 13 | 703 | 70 | 84 | 0 |
| 30 Sep 13 | 699 | 60 | 82 | 0 |
| 30 Jun 13 | 698 | 54 | 80 | 0 |
Quality Earnings: 954 is currently unprofitable.
Growing Profit Margin: 954 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 954 is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.
Accelerating Growth: Unable to compare 954's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 954 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11%).
Return on Equity
High ROE: 954 has a negative Return on Equity (-13.28%), as it is currently unprofitable.